This study looks at a new treatment for a type of blood cancer called Acute Myeloid Leukemia (AML). It uses three drugs: BP1001, venetoclax, and decitabine. BP1001 is a special treatment that stops the Grb2 protein, which helps cancer cells grow. Venetoclax and decitabine are medicines used for AML. The study compares how well these drugs work together against AML compared to older treatments.
AML patients who haven't been treated or who didn't get better with other treatments can join. The study will have three groups: one with all three drugs, one with BP1001 and decitabine, and one for those who can't use venetoclax.
- Duration: The study will continue until enough participants have been treated in each group.
- Eligibility: Participants must be 18 or older and meet specific health criteria.
- Safety: The study will monitor participants closely for any side effects.
If you join, you'll help researchers find better ways to treat AML. Always talk to your doctor to see if joining is right for you.